Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154047 · ClinicalTrials.gov registry record · Phase 2
Study in Subjects With Light Chain (AL) Amyloidosis
A Phase 2 study, sponsored by Prothena Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT03154047: Clinical Trial Phase 2 study, sponsored by Prothena Biosciences.
NCT03154047 is a Phase 2 study that was terminated before completion, run by Prothena Biosciences. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03154047, a Phase 2 study, was terminated before completion, sponsored by Prothena Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.
Primary Outcome
AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, o
Interventions
- DRUG NEOD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 2 |
Why NCT03154047 stopped before completion
NCT03154047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 1 intervention - of which NEOD001 is the first listed.
NCT03154047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03154047 about?
NCT03154047 is a clinical study titled "Study in Subjects With Light Chain (AL) Amyloidosis". The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.
What is the current status of trial NCT03154047?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2017-06-14. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT03154047?
The interventions under investigation include: NEOD001 (DRUG).
Who is sponsoring clinical trial NCT03154047?
This trial is sponsored by Prothena Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03154047's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI